USANA Q1 net sales $228M (-8% YoY), EPS $0.86, reaffirms FY2024 guidance

USANA HEALTH SCIENCES INC

2024-Q1 EPS reported $0.86 revenue$227,800,000

Net sales $228M (-8% YoY, -5% constant currency); diluted EPS $0.86 (-9% YoY).
Reiterates FY2024 net sales outlook $850-920M and EPS $2.40-$3.00.
Greater China active customers +15% YoY, net sales +3% (+7% constant currency).
Other key markets declined: North Asia net sales -28% YoY, SE Asia -22%, Americas/Europe -12%.
Repurchased 194k shares for $9M in Q1; $62M remaining under share repurchase authorization.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

USANA HEALTH SCIENCES INC reported first quarter ended March 30, 2024 results: revenue $228 million, EPS $0.86. Guidance reaffirmed.

Period: first quarter ended March 30, 2024
Revenue: $228 million
EPS: $0.86
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended March 30, 2024. Key Financial & Operating Results • First quarter net sales were $228 million versus $248 million during Q1 2023, and increased 2% sequentially in constant currency. • First quarter diluted EPS was $0.86 as compared with $0.95 during Q1 2023. • Company

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

USANA HEALTH SCIENCES INC filing history →

Source: SEC EDGAR

accession 0000896264-24-000138

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.